Frontiers opens a call for programmable immune-cell circuits in solid tumors
Solid tumors remain a difficult target for adoptive cell therapy because the biology of the tumor and the biology of the surrounding tissue rarely line up neatly. Antigen expression can vary from one tumor region to another, and even within the same lesion it can shift over time. Immune cells also have to work through hypoxia, metabolic stress, stromal exclusion, and suppressive signaling that blunt activity before a therapeutic cell ever reaches its target.
This Research Topic in Frontiers in Immunology is built around a simple but clinically demanding question: can engineered immune cells make better decisions than a fixed-response receptor design? The call focuses on programmable systems that integrate multiple inputs, use contextual sensing, and restrain effector activity when normal tissue is at risk. The scope is centered on solid tumor immunotherapy, where the distance between promising engineering and usable treatment has remained stubbornly wide.
A single antigen-recognition event is often too crude for solid tumors. A receptor that turns on whenever it encounters one marker can collide with the same marker on healthy tissue, especially when the target is shared at low levels or expressed heterogeneously. The Research Topic therefore emphasizes logic-gated designs, inducible programs, and safety circuits that let engineered cells distinguish tumor from non-tumor tissue with more precision than conventional CAR constructs.
Logic gates, contextual sensing, and the problem of tumor heterogeneity
The editors are inviting work on CAR, TCR, synNotch, and related synthetic receptor systems that interpret combinations of signals rather than a single cue. AND, OR, NOT, sequential, and hierarchical decision architectures all fall within scope, provided they address cancer immunotherapy rather than synthetic biology in the abstract. The central translational challenge is whether greater circuit complexity actually produces a better therapeutic index in realistic tumor settings.
A tumor that expresses one antigen in one compartment and a different one in another can defeat a simple lock-and-key model. The same is true when normal tissues share part of the target profile. Programmable immune cells are being positioned as a way to bind recognition to context, whether that context is antigen density, coexpression patterns, hypoxia, protease activity, cytokine exposure, or stromal cues. The Research Topic asks for designs that connect these inputs to measurable behavior, not just to elegant engineering diagrams.
The call also recognizes that success in a dish does not guarantee success in vivo. Solid tumors impose spatial barriers to infiltration, create pockets of nutrient deprivation, and encourage exhaustion through chronic stimulation. Studies that test circuit performance against antigen heterogeneity, immune exclusion, hypoxia, nutrient limitation, stromal restriction, and immunosuppression will fit the topic’s translational emphasis.
Safety switches and the clinical price of overactivation
Safety is not an afterthought in this area. It is the difference between a platform that can move forward and one that stops at proof of concept. The Research Topic specifically seeks integrated safety and reversibility mechanisms, exposure-limiting approaches, pharmacological control, and external control systems that can shut down or reshape activity if toxicity emerges.
This matters because the same engineering that boosts potency can also raise the cost of failure. A cell that is harder to silence, harder to predict, or harder to reverse can become a liability when it encounters a shared antigen or an inflamed normal tissue niche. The editors are asking authors to examine not just tumor killing, but the entire operating range of the cell: trafficking, persistence, fitness, exhaustion, memory formation, and resistance after repeated stimulation.
There is a practical clinical logic behind that emphasis. If a circuit produces strong tumor selectivity but leaves the cell exhausted after brief activation, the design may still fail at the bedside. If a construct persists but loses control over tissue selectivity, durability becomes a liability. Studies that measure both efficacy and restraint will carry the most weight in this topic.
Beyond killing: cytokines, chemokines, remodeling, and resistance
The scope is broader than direct cytotoxicity. The topic welcomes inducible cytokine, chemokine, engager, antibody, metabolic, and tissue-remodeling programs. It also includes work on macrophage, NK-cell, γδ T-cell, and NKT-cell platforms, not only conventional CAR-T designs. This breadth reflects a growing recognition that solid tumor therapy may require immune cells to do more than kill a target cell once they arrive.
Engineered cells may need to recruit additional immune effectors, alter local chemistry, or remodel the tumor niche so that infiltration and function become possible. They may also need to counteract antigen escape, circuit failure, and treatment resistance after the initial response fades. Those are not secondary endpoints in solid tumors; they often determine whether a therapy can produce durable disease control.
The call also encourages studies that use quantitative models, biomarkers, imaging approaches, and potency assays to validate cellular decision-making. A circuit that cannot be measured reliably is difficult to compare across platforms, and difficult to carry into clinical development. For that reason, translational frameworks that link construct design to reproducible readouts are a major priority.
Translation, manufacturing, and the limits of computation alone
Complex cell products bring their own hazards. Manufacturing consistency, genomic stability, immunogenicity, and regulatory feasibility all become more complicated as the number of engineered functions rises. The Research Topic explicitly asks authors to confront those issues rather than treating them as downstream problems.
One especially clear boundary is what will not be accepted: stand-alone bioinformatics or computational analyses of public genomic or transcriptomic databases without independent validation are out of scope. For this topic, engineering claims need biological support in vitro, in vivo, or in independent cohorts. That requirement reflects the section’s translational intent and its focus on immune-cell decision systems that can be evaluated in meaningful tumor models.
Frontiers is positioning this call within its cancer immunity and immunotherapy section, and the topic is open to a wide range of article types, including original research, methods, reviews, perspectives, clinical trial reports, and study protocols. The submission deadline is listed as 2 November 2027, giving investigators time to develop work that ties circuit architecture to clinically relevant endpoints.
What remains unresolved is not whether programmable immune cells can be designed, but which combinations of sensing, activation, restraint, and validation will matter enough to survive the move from elegant concept to usable therapy. The field will need studies that show where complexity helps, where it adds risk, and where a simpler circuit may still be the stronger clinical choice.